Mark W. Kubik

Mark Kubik practices at UPMC Presbyterian in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Mark Kubik's NPI, 1881937340, was assigned on April 3, 2013. Mark Kubik graduated from Baylor College of Medicine in 2013. Mark Kubik holds Pennsylvania license MD466957.

Mark Kubik's primary practice is UPMC Presbyterian, at 200 Lothrop Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 647-2345.

Mark Kubik's primary practice is UPMC Presbyterian in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Mark Kubik is also affiliated with Select Specialty Hospital - Pittsburgh / UPMC. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Mark Kubik to 5 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mark Kubik practices, 9 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Mark Kubik's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Mark Kubik is licensed in Pennsylvania.

CMS data shows 1,380 Medicare services from Mark Kubik across 12 procedure codes in 2024, for 559 Medicare patients. Medicare paid $76,654 for them. Every service was in an office.

CMS counts 559 Medicare patients who saw Mark Kubik in 2024. The largest group is 65 to 74, with 271 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 6% are also on Medicaid. Their average risk score is 1.23, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Mark Kubik's median patient age at 65, with 57% women.

In 2024, Mark Kubik wrote 1,099 Medicare Part D claims for 498 patients. 98% of them were for generic drugs. CMS names the drug for 1,018 of them, across 20 drugs with 11 or more claims each, at $18,038 in total drug cost. In 2023, CMS named 205 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Mark Kubik for performance year 2024, reported as part of a group. Mark Kubik accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Mark Kubik as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 57 papers to Mark Kubik, published from 2012 to 2024. 2021 was the busiest year, with 8. The most frequent topics are Head and Neck Neoplasms, Postoperative Complications and Free Tissue Flaps. Mark Kubik has published most often in Laryngoscope. Mark Kubik's most frequent co-authors are Mario Solari, Seungwon Kim and Robert Louis Ferris, MD.

CMS Open Payments shows 24 general payments to Mark Kubik from 9 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 44% of the total. Cook Medical LLC paid the most, $2,258.

Mark Kubik graduated from Baylor College of Medicine in 2013.